Lyell Immunopharma Inc (NASDAQ: LYEL) on Friday, soared 5.69% from the previous trading day, before settling in for the closing price of $0.41. Within the past 52 weeks, LYEL’s price has moved between $0.40 and $3.14.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 332.01%. The company achieved an average annual earnings per share of 43.61%. With a float of $124.83 million, this company’s outstanding shares have now reached $294.88 million.
Let’s determine the extent of company efficiency that accounts for 300 employees. In terms of profitability, gross margin is -16170.49%, operating margin of -591949.18%, and the pretax margin is -562285.25%.
Lyell Immunopharma Inc (LYEL) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Lyell Immunopharma Inc is 57.72%, while institutional ownership is 22.45%. The most recent insider transaction that took place on Mar 31 ’25, was worth 19,958. In this transaction Director of this company bought 35,640 shares at a rate of $0.56, taking the stock ownership to the 35,640 shares. Before that another transaction happened on Mar 21 ’25, when Company’s Director bought 200,000 for $0.58, making the entire transaction worth $115,220. This insider now owns 200,000 shares in total.
Lyell Immunopharma Inc (LYEL) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 43.61% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 21.29% during the next five years compared to -19.90% drop over the previous five years of trading.
Lyell Immunopharma Inc (NASDAQ: LYEL) Trading Performance Indicators
Lyell Immunopharma Inc (LYEL) is currently performing well based on its current performance indicators. A quick ratio of 7.06 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2157.64.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.31, a number that is poised to hit -0.18 in the next quarter and is forecasted to reach -0.72 in one year’s time.
Technical Analysis of Lyell Immunopharma Inc (LYEL)
Looking closely at Lyell Immunopharma Inc (NASDAQ: LYEL), its last 5-days average volume was 0.72 million, which is a drop from its year-to-date volume of 0.99 million. As of the previous 9 days, the stock’s Stochastic %D was 19.13%. Additionally, its Average True Range was 0.06.
During the past 100 days, Lyell Immunopharma Inc’s (LYEL) raw stochastic average was set at 5.92%, which indicates a significant decrease from 18.85% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 102.72% in the past 14 days, which was higher than the 87.32% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5851, while its 200-day Moving Average is $1.0121. However, in the short run, Lyell Immunopharma Inc’s stock first resistance to watch stands at $0.4545. Second resistance stands at $0.4705. The third major resistance level sits at $0.5012. If the price goes on to break the first support level at $0.4078, it is likely to go to the next support level at $0.3771. Should the price break the second support level, the third support level stands at $0.3611.
Lyell Immunopharma Inc (NASDAQ: LYEL) Key Stats
Market capitalization of the company is 129.46 million based on 295,229K outstanding shares. Right now, sales total 60 K and income totals -342,990 K. The company made 10 K in profit during its latest quarter, and -191,940 K in sales during its previous quarter.
